#85 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians should be aware that despite patient demand for cannabis as a mental health treatment, robust evidence does not support its use for depression, anxiety, or PTSD and may cause harm. This finding directly impacts clinical decision-making, as prescribing cannabis for these conditions lacks an evidence base and could delay evidence-based treatments like psychotherapy or antidepressants that have demonstrated efficacy. Patients with substance use disorders may face particular risks, including increased cravings, making cannabis counseling especially important during initial psychiatric assessments.
A comprehensive systematic review and meta-analysis found insufficient evidence that medical cannabis effectively treats depression, anxiety, or post-traumatic stress disorder, contrary to common patient expectations and emerging clinical use patterns. The analysis revealed that cannabis use was associated with increased adverse effects and, notably, elevated cocaine cravings in certain patient subgroups, suggesting potential harmful interactions in populations with comorbid substance use disorders. These findings are particularly relevant for clinicians who face increasing patient requests for cannabis as an alternative or adjunctive treatment for mood and anxiety disorders, as they underscore the absence of rigorous evidence supporting such indications. The study highlights a significant gap between patient demand and clinical evidence, especially given that mood and anxiety disorders represent commonly cited reasons for medical cannabis authorization in many jurisdictions. Clinicians should use these results to counsel patients realistically about efficacy, discuss established treatments with proven efficacy, and carefully screen for substance use history before considering cannabis in their treatment algorithms. Patients seeking cannabis for depression or anxiety should understand that evidence-based pharmacotherapies and psychotherapies remain the standard of care, and cannabis may carry risks rather than benefits for these conditions.
“After two decades in this field, I can tell you this study confirms what careful clinicians have suspected: we’ve been relying on patient anecdotes and desperation rather than evidence when recommending cannabis for psychiatric conditions, and that’s a failure of our due diligence to our patients who deserve treatments we actually know work.”
💊 While cannabis remains widely self-reported as helpful for mood and anxiety symptoms by patients, this landmark study adds to accumulating evidence that medical cannabis lacks robust efficacy for depression, anxiety, and PTSD in rigorous clinical trials. The finding of increased adverse effects and, in some populations, elevated cravings for other substances, raises important safety considerations that clinicians should discuss with patients seeking cannabis for these conditions. It is worth noting that heterogeneity in study designs, cannabis formulations, dosing regimens, and patient populations across trials can complicate definitive conclusions, and individual patient responses may vary based on factors not fully captured in group-level analyses. Nevertheless, from a clinical standpoint, this evidence suggests that patients presenting with mood or anxiety disorders should be counseled that conventional, evidence-based treatments such as psychotherapy and FDA-approved medications remain the standard first-line approach, while cannabis should not be recommended primarily for these indications despite its
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: